Bascom Palmer Angiogenesis - 2013 Brochure pdf

1:40 Real-world Utilization of Anti-VEGF Therapiesin Age-Related Macular DegenerationSzilárd Kiss, MD1:50 Non-infectious Endophthalmitis After Intravitreal InjectionFenghua Wang, MD2:00 IVAN Trial UpdateBarnaby Reeves, DPhil2:10 Top 5 Findings from the Comparison ofAMD Treatment TrialsDaniel F. Martin, MD2:20 VEGF Antagonism–Can You Have Too Much of aGood Thing?Martin Friedlander, MD, PhD2:30 High Dose Ranibizumab for Wet AMDAnne E. Fung, MD2:40 The Impact of Neutralizing Antibodies Against RanibizumabRobert L. Avery, MD2:50 Update on Aflibercept for Wet AMDJeffrey S. Heier, MD3:00 Comparison of Avastin/Lucentis with Eylea in Clinical PracticeJason S. Slakter, MD3:10 Anti-VEGF Therapy in ChinaXiaodong Sun, MD3:20 Anti-VEGF DARPin for Wet AMDDavid M. Brown, MD, FACS3:30 PDGF Inhibition in Wet AMD: Part 1Pravin U. Dugel, MD3:40 PDGF Inhibition in Wet AMD: Part 2Peter K. Kaiser, MD3:50 Radiation Therapy for Wet AMDDarius M. Moshfeghi, MD4:00 Refillable Drug Delivery Implant Providing SustainedRelease Anti-VEGF Therapy in Wet AMDAnat Loewenstein, MD4:10 Sustained VEGF Inhibition with Encapsulated Cell TechnologyGlenn J. Jaffe, MD4:20 Gene Transfer Trials for Wet AMD: U.S. ExperiencePeter A. Campochiaro, MD4:30 Gene Transfer Trials for Wet AMD: Australian ExperienceThomas W. Chalberg, PhD